Find out which of these stocks got a buyout bid.
News & Analysis: Ra Pharmaceuticals, Inc. Common Stock
Investors are cheering for successful results from a mid-stage trial with the company's lead candidate.
"Positive" phase 2 data for RA101495 SC wasn't positive enough.
Investors find fault in Ra's phase 2 initial data for its lead drug.